PRE-ISPY Phase I/II (I-SPY-P1) is an open-label, multisite platform study with multiple ongoing drug regimen arms added by protocol amendment which is designed…

HER2-positive Breast CancerMetastatic CancerMetastatic Breast Cancer+29 more

~Estimated

~$10 – $7,500

QuantumLeap Healthcare CollaborativeNCT05868226

Phase 2

A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206)

The purpose of this study is to evaluate the efficacy and safety of zanidatamab for the treatment of participants with previously treated solid tumors that hav…

Breast CancerGastric CancerEsophageal Cancer+9 more

~Estimated

~$10 – $8,750

Jazz PharmaceuticalsNCT06695845

Phase 1

Phase I Study of HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma (HEROS 3.0)

The purpose of this study is to learn whether it is safe to give HER2-CAR T cells in combination with an immune checkpoint inhibitor drug (pembrolizumab or niv…

SarcomaHER-2 Protein OverexpressionOsteosarcoma+5 more

~Estimated

~$10 – $6,250

Baylor College of MedicineNCT04995003